PAVmed Inc. (PAVM)
NASDAQ (CM) NASDAQ (CM) Primary 
PAVmed Inc. (PAVM) Q1 2026 Earnings Call Transcript
PAVmed Inc. (PAVM) Q1 2026 Earnings Call Transcript
PAVmed Inc. (PAVM) Reports Q1 Loss, Lags Revenue Estimates
PAVmed Inc. (PAVM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $2.1 per share a year ago.
Will PAVmed Inc. (PAVM) Report Negative Earnings Next Week? What You Should Know
PAVmed (PAVM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PAVmed (NASDAQ:PAVM) Shares Pass Below 50-Day Moving Average – Time to Sell?
PAVmed Inc. (NASDAQ: PAVM - Get Free Report)'s stock price crossed below its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $9.86 and traded as low as $9.15. PAVmed shares last traded at $9.37, with a volume of 8,140 shares. Analyst Ratings Changes A number of brokerages recently
PAVM Assigns Joseph Virgilio to Lead Medical Device Portfolio Relaunch
PAVmed taps industry veteran Joseph Virgilio to lead its device portfolio relaunch to boost growth, commercialization and long-term shareholder value.
PAVmed Inc. (PAVM) Q4 2025 Earnings Call Transcript
PAVmed Inc. (PAVM) Q4 2025 Earnings Call Transcript
PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know
PAVmed (PAVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript
PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript
PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript
PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript
PAVmed Inc. (PAVM) Q1 2025 Earnings Call Transcript
PAVmed Inc. (NASDAQ:PAVM ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director of Investor Relations Lishan Aklog - Chairman and Chief Executive Officer Dennis McGrath - Chief Financial Officer Conference Call Participants Jeremy Pearlman - Maxim Group Edward Woo - Ascendiant Capital Operator Good morning, and welcome to the PAVmed's First Quarter 2025 Business Update Conference Call. At this time, all lines are in a listen-only mode.
PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know
PAVmed (PAVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PAVmed Inc. (PAVM) Q4 2024 Earnings Call Transcript
PAVmed Inc. (NASDAQ:PAVM ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Jeremy Pearlman - Maxim Group Matthew Park - Cantor Fitzgerald Ed Woo - Ascendiant Capital Operator Good morning, and welcome to PAVmed's Fourth Quarter 2024 Business Update Conference Call. At this time, all lines are in a listen-only mode.
